ANKRD30BL

Across TCGA pan-cancer cohorts, ANKRD30BL Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ANKRD30BL data layer compared with 16 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher ANKRD30BL Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ANKRD30BL expression acts as an unfavorable survival marker.

ESCA, LIHC, and SKCM are the cancer types where ANKRD30BL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	All	0.252	0.708	<.001	12	view →
LIHC	DFS	Median	All	0.081	0.555	<.001	12	view →
SKCM	OS	Median	All	0.179	0.781	<.001	9	view →
COAD	OS	Median	II,III,IV	0.168	0.788	.005	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ANKRD30BL–ESCA (OS)

Open the ESCA breakdown →